| abstract |
The invention relates to an allosteric alkyne inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, including celecoxib, or a pharmaceutically acceptable salt thereof, or a combination of valdecoxib, or a pharmaceutically acceptable salt thereof. provide. The present invention also provides a method for treating a disease responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising an allosteric alkyne inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, Alternatively, a method comprising administering to a patient suffering from such a disease a pharmaceutically acceptable salt thereof, or valdecoxib, or a combination of the present invention with a pharmaceutically acceptable salt thereof is provided. The invention also relates to an allosteric alkyne inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising a combination of the present invention and a pharmaceutically acceptable carrier, diluent or excipient are provided. Also, the combinations of the present invention can be further combined with other pharmaceuticals depending on the disease being treated. |